Regeneron Pharmaceuticals, Inc. (FRA:RGO)
Germany
· Delayed Price · Currency is EUR 535.60
+40.00 (8.07%)
At close: May 2, 2025, 10:00 PM CET
Regeneron Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 4,499 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade
|
| Depreciation & Amortization | 495.7 | 482.9 | 421 | 341.4 | 286.2 | 235.9 | Upgrade
|
| Asset Writedown & Restructuring Costs | 12.6 | 12.6 | - | 195 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -454.3 | -118.3 | 266.4 | 36.8 | -387 | -221.8 | Upgrade
|
| Stock-Based Compensation | 1,008 | 982.8 | 885 | 725 | 601.7 | 432 | Upgrade
|
| Other Operating Activities | -679.4 | -733.8 | -837.9 | -378.4 | 421.6 | 162.4 | Upgrade
|
| Change in Accounts Receivable | -343 | -554 | -338.8 | 707.8 | -1,927 | -1,356 | Upgrade
|
| Change in Inventory | -616.2 | -619.7 | -271.7 | -696.5 | -494.3 | -529.4 | Upgrade
|
| Change in Accounts Payable | 410.5 | 735.1 | 598.6 | -138.4 | 866.1 | 118.9 | Upgrade
|
| Change in Unearned Revenue | 128.6 | 227.8 | 37.9 | 32.4 | -120.2 | 148.1 | Upgrade
|
| Change in Other Net Operating Assets | -509.1 | -407.5 | -120.1 | -148.6 | -240.7 | 114.9 | Upgrade
|
| Operating Cash Flow | 3,953 | 4,421 | 4,594 | 5,015 | 7,081 | 2,618 | Upgrade
|
| Operating Cash Flow Growth | -16.58% | -3.78% | -8.39% | -29.18% | 170.47% | 7.74% | Upgrade
|
| Capital Expenditures | -851.3 | -755.9 | -718.6 | -590.1 | -551.9 | -614.6 | Upgrade
|
| Sale of Property, Plant & Equipment | 20.1 | 20.1 | - | - | - | - | Upgrade
|
| Cash Acquisitions | -16.5 | -16.5 | -54.9 | -230.3 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -140 | -125.7 | -207.8 | -1,027 | - | - | Upgrade
|
| Investment in Securities | 854.2 | -1,590 | -2,204 | -1,937 | -4,833 | 544 | Upgrade
|
| Investing Cash Flow | -133.5 | -2,468 | -3,185 | -3,785 | -5,385 | -70.6 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 1,500 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 1,982 | Upgrade
|
| Total Debt Issued | - | - | - | - | - | 3,482 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -1,500 | Upgrade
|
| Total Debt Repaid | - | - | - | - | - | -1,500 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | - | - | 1,982 | Upgrade
|
| Issuance of Common Stock | 843.8 | 1,465 | 1,146 | 1,520 | 1,672 | 2,575 | Upgrade
|
| Repurchase of Common Stock | -4,043 | -3,632 | -2,936 | -2,529 | -2,678 | -6,528 | Upgrade
|
| Other Financing Activities | -43.7 | -33.4 | - | - | - | - | Upgrade
|
| Financing Cash Flow | -3,337 | -2,201 | -1,790 | -1,009 | -1,006 | -1,971 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.4 | -0.7 | -0.4 | - | - | - | Upgrade
|
| Net Cash Flow | 483.2 | -248.8 | -381.6 | 221.3 | 690.8 | 577 | Upgrade
|
| Free Cash Flow | 3,102 | 3,665 | 3,875 | 4,425 | 6,529 | 2,004 | Upgrade
|
| Free Cash Flow Growth | -23.69% | -5.44% | -12.42% | -32.23% | 225.90% | 0.15% | Upgrade
|
| Free Cash Flow Margin | 22.02% | 25.80% | 29.54% | 36.35% | 40.63% | 23.58% | Upgrade
|
| Free Cash Flow Per Share | 27.18 | 31.84 | 34.08 | 38.98 | 58.19 | 17.41 | Upgrade
|
| Cash Interest Paid | 52.6 | 52.6 | 73.1 | 53.7 | 55.8 | 23.2 | Upgrade
|
| Cash Income Tax Paid | 743 | 743 | 870.3 | 1,502 | 1,218 | 188.1 | Upgrade
|
| Levered Free Cash Flow | 2,083 | 2,636 | 2,763 | 2,628 | 4,309 | 1,192 | Upgrade
|
| Unlevered Free Cash Flow | 2,113 | 2,670 | 2,808 | 2,665 | 4,345 | 1,227 | Upgrade
|
| Change in Net Working Capital | 884.6 | 504.4 | 217.1 | -94.5 | 1,613 | 1,117 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.